Clinical Trial Update: Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention [Phase 2]

View source ↗

Summary

A Phase 2 extension study to evaluate the safety and efficacy of repeat ABP-450 injections for migraine prevention has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• ABP-450

Snippet

Sponsor: AEON Biopharma, Inc. | Conditions: Migraine | Phase 2 | Status: TERMINATED